×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADMA – adma biologics inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADMA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/24
01:30 pm
adma
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow [Yahoo! Finance]
Neutral
Report
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow [Yahoo! Finance]
12/20
07:00 am
adma
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Low
Report
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
12/13
05:15 pm
adma
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Low
Report
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
12/12
05:45 pm
adma
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Low
Report
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
12/11
06:15 pm
adma
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
Medium
Report
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
12/10
05:30 pm
adma
The Schall Law Firm Urges Shareholder Contributions To An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
Low
Report
The Schall Law Firm Urges Shareholder Contributions To An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
12/10
03:13 pm
adma
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip? [Yahoo! Finance]
Neutral
Report
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip? [Yahoo! Finance]
12/9
05:45 pm
adma
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm
Low
Report
ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/20
07:06 am
adma
Form 8-K ADMA BIOLOGICS, INC. For: Dec 20
Low
Report
Form 8-K ADMA BIOLOGICS, INC. For: Dec 20
12/2
09:03 pm
adma
Form 4 ADMA BIOLOGICS, INC. For: Nov 27 Filed by: ELMS STEVE
Low
Report
Form 4 ADMA BIOLOGICS, INC. For: Nov 27 Filed by: ELMS STEVE
11/22
09:06 pm
adma
Form 4 ADMA BIOLOGICS, INC. For: Nov 22 Filed by: Grossman Adam S
Low
Report
Form 4 ADMA BIOLOGICS, INC. For: Nov 22 Filed by: Grossman Adam S
11/22
09:06 pm
adma
Form 4 ADMA BIOLOGICS, INC. For: Nov 22 Filed by: Tade Brad L.
Low
Report
Form 4 ADMA BIOLOGICS, INC. For: Nov 22 Filed by: Tade Brad L.
11/22
09:01 pm
adma
Form 144 ADMA BIOLOGICS, INC. Filed by: Tade Brad L.
Low
Report
Form 144 ADMA BIOLOGICS, INC. Filed by: Tade Brad L.
11/22
09:01 pm
adma
Form 144 ADMA BIOLOGICS, INC. Filed by: Grossman Adam S
Low
Report
Form 144 ADMA BIOLOGICS, INC. Filed by: Grossman Adam S
11/21
04:31 pm
adma
Form 8-K ADMA BIOLOGICS, INC. For: Nov 19
Low
Report
Form 8-K ADMA BIOLOGICS, INC. For: Nov 19
11/12
01:35 pm
adma
Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/20
Form 8-K ADMA BIOLOGICS, INC. For: Mar 20
36.6%
1/9 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook 17.6%
3/3 Form 4 ADMA BIOLOGICS, INC. For: Feb 28 Filed by: Grossman Adam S 10.8%
3/10 Form SEC STAFF LETTER ADMA BIOLOGICS, INC. 8.6%
5/21 ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 8.5%
8/23 Form 8-K ADMA BIOLOGICS, INC. For: Aug 23 7.7%
9/5 Form 8-K ADMA BIOLOGICS, INC. For: Aug 29 7.3%
5/8 Q1/2019 3/31/2019 EPS -0.280 ZacksConsensus -0.320 ActVsEst 0.040 - Beat 7.3%
7/8 Form 8-K ADMA BIOLOGICS, INC. For: Jul 02 6.9%
10/21 ADMA Biologics Announces First Commercial Sales of ASCENIV™ 6.5%
1/9 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook 17.6%
3/3 Form 4 ADMA BIOLOGICS, INC. For: Feb 28 Filed by: Grossman Adam S 10.8%
3/10 Form SEC STAFF LETTER ADMA BIOLOGICS, INC. 8.6%
5/21 ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 8.5%
8/23 Form 8-K ADMA BIOLOGICS, INC. For: Aug 23 7.7%
9/5 Form 8-K ADMA BIOLOGICS, INC. For: Aug 29 7.3%
5/8 Q1/2019 3/31/2019 EPS -0.280 ZacksConsensus -0.320 ActVsEst 0.040 - Beat 7.3%
7/8 Form 8-K ADMA BIOLOGICS, INC. For: Jul 02 6.9%
10/21 ADMA Biologics Announces First Commercial Sales of ASCENIV™ 6.5%
TOP News Decliners
2/6
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
-14.3%
6/6 Form 8-K ADMA BIOLOGICS, INC. For: Jun 06 -12.3%
10/2 Form 8-K ADMA BIOLOGICS, INC. For: Oct 02 -11.2%
11/6 Form 8-K ADMA BIOLOGICS, INC. For: Nov 06 -10.5%
3/5 ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -10.4%
3/3 New U.S. patent lifts Adma Biologics, up 17% premarket [Seeking Alpha] -9.9%
3/16 ADMA Biologics Inc (NASDAQ: ADMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $14.00. -9.1%
10/3 Form 8-K ADMA BIOLOGICS, INC. For: Oct 03 -8.5%
3/9 Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: BlackRock Inc. -7.5%
12/3 ADMA Biologics Inc (NASDAQ: ADMA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.0%
6/6 Form 8-K ADMA BIOLOGICS, INC. For: Jun 06 -12.3%
10/2 Form 8-K ADMA BIOLOGICS, INC. For: Oct 02 -11.2%
11/6 Form 8-K ADMA BIOLOGICS, INC. For: Nov 06 -10.5%
3/5 ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -10.4%
3/3 New U.S. patent lifts Adma Biologics, up 17% premarket [Seeking Alpha] -9.9%
3/16 ADMA Biologics Inc (NASDAQ: ADMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $14.00. -9.1%
10/3 Form 8-K ADMA BIOLOGICS, INC. For: Oct 03 -8.5%
3/9 Form SC 13G/A ADMA BIOLOGICS, INC. Filed by: BlackRock Inc. -7.5%
12/3 ADMA Biologics Inc (NASDAQ: ADMA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: